

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Scoping

#### **MTA - Denosumab for the treatment of bone metastases from solid tumours and multiple myeloma**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes. One of the consultees commented that an issue is the sex of patients with prostate and breast cancer.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

It is not considered that patient sex in prostate cancer reflects an equalities issue. Denosumab will be appraised within its licensed indication and based on the evidence submitted - in relation to breast cancer, if relevant, this could include consideration of equality issues around patient sex.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

to the matrix been made?
No

**Approved by Associate Director (name):** Frances Sutcliffe

**Date:** 20 May 2011